|
||||
Published by : PROFESSIONAL MEDICAL PUBLICATIONS |
||||
ISSN 1681-715X |
||||
|
||||
- |
||||
ORIGINAL ARTICLE |
||||
- |
||||
Volume 23 |
October - December 2007 (Part-I) |
Number 5 |
||
|
||||
|
Comparison of patients quality of life treated with two
different regimens for advanced gallbladder cancerAbdul Qayyum1, S.H.M. Zaidi2
ABSTRACT
Objective: Still there is no standard regimen for the treatment of patients with advanced gallbladder malignancy who suffer from poor quality of life. Hence we wanted to evaluate the quality of life in patients with advanced gallbladder cancer treated with either 5-fluorouracil (5-Fu) and Folinic acid (FA) or with Gemcitabine (Gem) plus Cisplatin (Cis).
Methodology: Records of all patients, including quality of life questionnaire were reviewed retrospectively. These patients with unresectable locally advanced or metastatic adenocarcinoma of gallbladder were seen in oncology clinic at Ziauddin Hospital and Baqai Institute of Oncology Karachi. Out of 40 patients, twenty received 5-FU with Folinic Acid (FA) (Group-1) and remaining twenty patients received Gem plus Cis (Group-2).
Results: In Group-I, out of twenty patients, two (10%) were males and eighteen (90%) were females. Eleven (55%) patients showed relief in few symptoms for a mean duration of 5.9 (±3.3) months. There was no major impact of treatment on improving quality of life. In Group-II, out of twenty, three (15%) were males and seventeen (85%) were female patients who were treated with Gemcitabine plus Cisplatin.In this group sixteen (80%) patients showed a significant improvement in quality of life with relief of many symptoms for a mean duration of 6.2 (±3.4) months.
Conclusions: Gemcitabine plus Cisplatin is effective in the management of patients with advanced gallbladder cancer and showed improvement in quality of life as compared to, 5-Fu with FA which does not result in improving the quality of life and is ineffective.
Key Words: Gall bladder cancer, Quality of life, 5-fluorouracil, Folinic acid, Gemcitabine, Cisplatin.
Pak J Med Sci October - December (Part-I) 2007 Vol. 23 No. 5 703-707
1. Abdul Qayyum,
Consultant Oncologist,
PATEL Hospital,
Karachi - Pakistan.
2. S.H.M. Zaidi,
Medical Director,
Baqai Institute of Oncology,
Karachi – Pakistan.
Correspondence
Dr. Abdul Qayyum,
E-mail: abqayyum@consultant.com
* Received for Publication: June 8, 2007
* Accepted: July 5, 2007
HOME | SEARCH | CURRENT ISSUE | PAST ISSUES
Professional
Medical Publications
Room No. 522, 5th Floor, Panorama Centre
Building No. 2, P.O. Box 8766, Saddar, Karachi - Pakistan.
Phones : 5688791, 5689285 Fax : 5689860
pjms@pjms.com.pk